Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · February 27, 2024

Safety, Efficacy, and Determinants of Response of Allogeneic CD19-Specific CAR NK Cells in CD19+ B-Cell Tumors

Nature Medicine


Additional Info

Nature Medicine
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
Nat. Med. 2024 Jan 18;[EPub Ahead of Print], D Marin, Y Li, R Basar, H Rafei, M Daher, J Dou, V Mohanty, M Dede, Y Nieto, N Uprety, S Acharya, E Liu, J Wilson, P Banerjee, HA Macapinlac, C Ganesh, PF Thall, R Bassett, M Ammari, S Rao, K Cao, M Shanley, M Kaplan, C Hosing, P Kebriaei, LJ Nastoupil, CR Flowers, SM Moseley, P Lin, S Ang, UR Popat, MH Qazilbash, RE Champlin, K Chen, EJ Shpall, K Rezvani

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading